Emilie Cayssials E

6PUBLICATIONS
10CO-AUTHORS
Predictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Nov 07, 2024
Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.

F Huguet, A Guerci-Bresler, G Roth-Guepin

|May 15, 2023
Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.

Thomas Systchenko, Jean-Claude Chomel, Pilar Gallego-Hernanz

|Oct 10, 2022
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).

Lydia Roy, Jean-Claude Chomel, Joëlle Guilhot

|Oct 23, 2020
Reply to Comment on low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.

Emilie Cayssials, Jose Torregrosa-Diaz, Xavier Leleu

|May 28, 2020
Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.

Emilie Cayssials, Jose Torregrosa-Diaz, Pilar Gallego-Hernanz

|Mar 14, 2019
Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells.

Emilie Cayssials, Florence Jacomet, Nathalie Piccirilli

Pageof 1

Frequent Collaborators

4 joint publications

Jean-Claude Chomel

2 joint publications

Lydia Roy

2 joint publications

Gabriel Etienne

2 joint publications

Franck E Nicolini